Status:
COMPLETED
Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in Europe. The aim of this trial is to compare two different active treatment regimens of biphasic insulin aspart in subjects with type 2 diabetes.
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Duration of diabetes for longer than 12 months
- Body mass index (BMI) below 35.0 kg/m\^2
- HbA1c below 11.0 %
- Treatment with BHI (biphasic human insulin) 20 or 30 twice daily for at least three months and in the last month as sole anti-diabetic treatment (i.e., no additional oral hypoglycaemic medication or daily use of short-acting insulin supplement)
Exclusion
- Current treatment with agents affecting glucose metabolism
- History of drug or alcohol dependence
- Impaired hepatic function
- Impaired renal function
- Cardiac disease
- Proliferative retinopathy
- Recurrent severe hypoglycaemia or advanced neuropathy
Key Trial Info
Start Date :
March 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 1999
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01520753
Start Date
March 1 1999
End Date
June 1 1999
Last Update
January 4 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Århus C, Denmark, 8000